Estrella Immunopharma, Inc. filed its S-4/A on Dec 19, 2022 for the period ending Jun 30, 2022. In this report its auditor, Friedman LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9468 USD | +7.59% | -4.56% | -14.70% |
1st Jan change | Capi. | |
---|---|---|
-14.70% | 34.44M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ESLA Stock
- News Estrella Immunopharma, Inc.
- Estrella Immunopharma, Inc. Auditor Raises 'Going Concern' Doubt